TODAY'S HEADLINES

Muscular dystrophy drug launch halts after pricing concerns

A drug manufacturer is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy after concerns over the drug's high price tag. Read more

New bladder cancer, kidney disease therapies available

FDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma and a treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Read more

CONTINUING PHARMACY EDUCATION

New options when statins are not enough

This month's CE activity, "New options when statins are not enough," is open for pharmacists and pharmacy technicians.
The goal of this activity is to prepare pharmacists with the knowledge they need to have to provide contemporary pharmacologic therapy to patients with hyperlipidemia.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Diabetic patients challenge insulin makers

In the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers. Find out why

February 15, 2017

Managed Care Pharmacy Survey 2017

Take three minutes to answer our managed care pharmacy survey. As a thank-you to survey-takers, when the survey closes, we will hold a drawing to give away not one, but two $200 Visa gift cards. Take survey.

Related Articles

FDA approves first drug for Duchenne muscular dystrophy

FDA expands Opdivo use for metastatic melanoma